HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients-Reference-Cited by-同舟云学术

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients

Published:2020-07 Issue:7 Volume:31 Page:902-911
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Shim J.H.,Kim H.S.,Cha H.,Kim S.,Kim T.M.,Anagnostou V.,Choi Y.-L.,Jung H.A.,Sun J.-M.,Ahn J.S.,Ahn M.-J.,Park K.,Park W.-Y.,Lee S.-H.

Funder

LUNGevity Foundation

V Foundation for Cancer Research

American College of Radiology Imaging Network

National Research Foundation of Korea

Foundation for the National Institutes of Health

Ministry of Trade, Industry and Energy

Allegheny Health Network

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference24 articles.

1. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy;Havel;Nat Rev Cancer,2019

2. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer;Hellmann;Cancer Cell,2018

3. Tumor mutational load predicts survival after immunotherapy across multiple cancer types;Samstein;Nat Genet,2019

4. Genomic correlates of response to immune checkpoint blockade;Keenan;Nat Med,2019

5. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma;Skoulidis;Cancer Discov,2018

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumour mutational burden: clinical utility, challenges and emerging improvements;Nature Reviews Clinical Oncology;2024-08-27

2. Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer;Med;2024-08

3. Peptide-stimulated T cells bypass immune checkpoint inhibitor resistance and eliminate autologous microsatellite instable colorectal cancer cells;npj Precision Oncology;2024-07-29

4. A novel artificial intelligence network to assess the prognosis of gastrointestinal cancer to immunotherapy based on genetic mutation features;Frontiers in Immunology;2024-06-27

5. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features;Nature Cancer;2024-06-03